Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their ex...
CHICAGO/TOKYO - Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer’s disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.
Markets in Japan were closed for a national holiday so the impact of the news on Eisai will be delayed. Any successful treatment for Alzheimer’s, which affects about 5.7 million Americans, is virtually guaranteed to become one of the world’s top-selling drugs. But efforts so far have had a dismal track record, with more than 100 failures.
Guggenheim analyst Yatin Suneja said Biogen instead should be looking to build its pipeline through acquisitions.Suneja said Biogen has about $42 billion in financing capacity and identified potential acquisition targets such as Sage Therapeutics Inc , GW Pharmaceuticals and Zogenix Inc that are “very interesting companies that should be considered now, more seriously.
Many companies including Biogen, Eisai, Lilly and AbbVie, are pursuing alternative approaches, such as focusing on tau, another Alzheimer’s protein that is more closely linked with the onset of symptoms.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Baca lebih lajut »
Biogen scraps Alzheimer drug trials, wiping $17 billion off its market valueReuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t...
Baca lebih lajut »
Biogen heads for the worst day in a decade after ending trial for blockbuster Alzheimer's drugShares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab.
Baca lebih lajut »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Baca lebih lajut »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Baca lebih lajut »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Baca lebih lajut »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street.
Baca lebih lajut »
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday.
Baca lebih lajut »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
Baca lebih lajut »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open.
Baca lebih lajut »